Therapeutic effects of clozapine on tardive dyskinesia

Nair, Chand; Abraham, George; Stanilla, Joseph K.; Tracy, Joseph B.; Leon, José de; Simpson, George M.; Josiassen, Richard C.

doi:10.1016/s1077-7229(98)80024-2

Cited by 11 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While TD has been reported with risperidone and olanzapine, there is no convincing report of TD with clozapine monotherapy and this may indeed be the safest drug [5]. Clozapine is only partially successful in suppressing TD, is considered to permit the remission of TD [66] and has been proposed as a treatment for TD and TDt [67]. In an analysis of seven 1-year trials of risperidone, the incidence of TD at relatively high doses (mean = 7.6-9.4 mg/d), was estimated at 0.3% [68].…”

Section: Neuroleptic Drugsmentioning

confidence: 99%

The Current Status of Tardive Dyskinesia

Sachdev

2000

Aust N Z J Psychiatry

101

View full text Add to dashboard Cite

show abstract

Section: Neuroleptic Drugsmentioning

confidence: 99%

The Current Status of Tardive Dyskinesia

Sachdev

2000

Aust N Z J Psychiatry

101

View full text Add to dashboard Cite

show abstract

“…While TD has been reported with risperidone and olanzapine, there is no convincing report of TD with clozapine monotherapy and this may indeed be the safest drug [5]. Clozapine is only partially successful in suppressing TD, is considered to permit the remission of TD [66] and has been proposed as a treatment for TD and TDt [67]. In an analysis of seven 1‐year trials of risperidone, the incidence of TD at relatively high doses (mean = 7.6–9.4 mg/d), was estimated at 0.3%[68].…”

Section: Risk Factorsmentioning

confidence: 99%

The current status of tardive dyskinesia

Sachdev

2000

Aust N Z J Psychiatry

View full text Add to dashboard Cite

show abstract

“…Further evidence that clozapine’s effect relates to suppression of movements, versus treatment per se, arises when the issue of dose is examined. Use of higher doses can suppress TD (Nair et al, 1998). When 23 subjects in a 48-week double-blind dose-response study received clozapine at three doses, 100 mg/d, 300 mg/d, or 600 mg/d each for 16 weeks, improved TD as measured by the Abbreviated Dyskinesia Rating Scale (ADRS) presented in only those receiving a clozapine dose of 600 mg/d (Nair et al, 1998).…”

Section: Discussionmentioning

confidence: 99%

“…Use of higher doses can suppress TD (Nair et al, 1998). When 23 subjects in a 48-week double-blind dose-response study received clozapine at three doses, 100 mg/d, 300 mg/d, or 600 mg/d each for 16 weeks, improved TD as measured by the Abbreviated Dyskinesia Rating Scale (ADRS) presented in only those receiving a clozapine dose of 600 mg/d (Nair et al, 1998). This same finding has been corroborated in several case reports (Shrivastava et al, 2009; Uzun et al, 2001).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review

et al. 2019

View full text Add to dashboard Cite

Background: It is commonly recommended that a switch to clozapine be implemented in the face of tardive dyskinesia, even if current treatment involves another “atypical” agent. However, reports do indicate clozapine carries a liability for tardive dyskinesia. Aims: This review sought to evaluate clozapine in relation to tardive dyskinesia in the context of available evidence. Methods: Medline, Embase, and PsycINFO databases were searched for studies published in English, using the keywords: clozapine AND tardive dyskinesia OR TD. References from major review articles were searched for additional relevant publications. Studies were included if they investigated: tardive dyskinesia in clozapine-treated patients diagnosed with schizophrenia spectrum disorders, and reported on two or more assessments of tardive dyskinesia severity measured by the Abnormal Involuntary Movement Scale; or clozapine’s tardive dyskinesia liability. Results: In total, 513 unique citations were identified and 29 reports met the inclusion criteria. Thirteen studies suggest clozapine reduces dyskinetic symptoms over time ( n=905 clozapine-treated participants); however, the minimum required dose and effect of withdrawal requires further investigation. The majority of reports which address clozapine’s liability for tardive dyskinesia are case studies (11 of 14 reports, 79%), and clozapine was only the first-line treatment in one of the remaining three studies reporting treatment-emergent dyskinetic symptoms with clozapine in 12% of patients. No significant between-drug differences were identified comparing clozapine’s risk to other atypical antipsychotics. Conclusions: Research to date supports switching to clozapine for the purpose of reducing tardive dyskinesia risk and/or treating existing tardive dyskinesia, but prospective randomized controlled trials are necessary if we are to substantiate existing recommendations.

show abstract

Therapeutic effects of clozapine on tardive dyskinesia

Cited by 11 publications

References 16 publications

The Current Status of Tardive Dyskinesia

The Current Status of Tardive Dyskinesia

The current status of tardive dyskinesia

Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review

Contact Info

Product

Resources

About